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A 46-year-old female presents with a pelvic mass and is diagnosed as having a high-grade endometrial stromal sarcoma.
During surgery, she is noted to have areas of intussusception of the small bowel secondary to large hamartomatous
polyps. The patient had a previous history of small bowel obstruction secondary to what had been thought to be
hyperplastic polyps but represented hamartomatous polyps on further review. Additional examination revealed the
presence of subtle hyperpigmented macules on the fingers leading to a diagnosis of Peutz-Jeghers Syndrome (PJS). The
diagnosis was confirmed by the presence of a germ-line STK11 mutation. Immunohistochemistry analysis of the tumor
showed decreased expression of STK-11 as compared to one of the patient’s hamartomatous polyps. Next generation
sequencing of the tumor specimen failed to demonstrate a “second hit” somatic mutation in STK-11. This case represents
the first case of endometrial stromal sarcoma associated with PJS and illustrates the importance of increased awareness of
this condition among oncologists. PJS is associated with dysregulation of the mTOR pathway; treatment with an mTOR
inhibitor was not effective in this case.
Keywords: Peutz-Jeghers syndrome, Endometrial stromal sarcomas, Soft tissue sarcomas, Gynecologic oncology,
EverolimusBackground
Peutz-Jeghers syndrome (PJS) is a rare, inherited disease,
with an estimated incidence of one in 100,000. It is an
autosomal dominant condition characterized by the devel-
opment of hamartomatous polyps throughout the gastro-
intestinal tract (most commonly seen in the small bowel,
particularly the jejunum), characteristic mucocutaneous
pigmented lesions and elevated cancer risk [1-3].
Polyps may cause gastrointestinal bleeding, intussus-
ception, obstruction, or infarction [1,4]. The melanotic
or lentiginous pigmented macules are usually located on
the vermilion border of the lips, buccal mucosa, digits,
and less frequently on the periorbital, auricular, perianal
and vulvar skin [2]. Most patients are diagnosed early in* Correspondence: gcolonotero@mayo.edu
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article, unless otherwise stated.life when they present with polyp-related complications.
Malignant transformation of the polyps is rare.
This genetic condition is caused by a germline mutation
in the tumor suppressor gene serine threonine kinase 11
gene (STK11, also known as LKB1) [5]. It is thought that
all patients with PJS have a deleterious mutation in STK11,
but current technology detects a mutation in only 75% of
cases. The diagnosis does not usually require genetic con-
firmation; it can be made based on clinical presentation.
Diagnostic criteria are outlined in Table 1 [6].
Although the mechanism of carcinogenesis remains
debatable, PJS patients carry an increased risk for the de-
velopment of cancers of the gastrointestinal tract (colon,
stomach, small intestine, and pancreas) as well as of
non-gastrointestinal origin (breast and gynecological tu-
mors) [4,7].
PJS has not been associated with soft tissue sarcomas.
In this article, we report the first case of a Peutz-Jeghers
Syndrome patient with an endometrial stromal sarcoma.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Diagnostic criteria for Peutz Jeghers Syndrome (PJS)
A. In patients without a family history of PJS, one of the following must be
present:
• Characteristic melanotic macules and one or more intestinal polyps
with PJS-type histology*, or
• Two intestinal polyps with PJS-type histology*
B. In patients with a family history of PJS in a first degree relative, one of the
following must be present:
• Characteristic melanotic macules, or
• One intestinal polyp with PJS-type histology*, or
• STK11 mutation
*PJS type histology defined as smooth muscle arborization.
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A 46-year-old woman presented with sensation of pressure
in her pelvis. A CT scan of the abdomen and pelvis
showed an 8 × 7 cm pelvic mass. Serum CA 125 level was
280 U/ml and serum CEA value was within normal limits.
The patient underwent an exploratory laparotomy with
findings of an 8 cm pelvic mass thought to be associated
with an area of endometriosis with involvement of the pel-
vic cul-de-sac and pelvic retroperitoneum. Pathology was
most consistent with a high grade endometrial stromal sar-
coma. Adequate surgical cytoreduction and staging with
hysterectomy, bilateral salpingo-oophorectomy, omentect-
omy, nodal sampling, and peritoneal washings were per-
formed. No additional areas of tumor involvement were
noted; specifically, there was no gross evidence of malig-
nancy involving the uterus, fallopian tubes, or ovaries.
During inspection of the small intestine, an area of in-
tussusception was noted, with resection revealing the
presence of two large pedunculated polyps (3.2 and
3.0 cm) as the cause of the intussusception. Suspicion of
PJS was raised by intraoperative consultation with med-
ical genetics based on the presence of pedunculated
small bowel polyps and additional findings on physical
examination of the patient, which included multiple hy-
perpigmented areas on her fingertips (Figure 1A).
Pathological examination showed a 9.5 cm malignant
neoplasm consistent with high-grade endometrioid stro-
mal sarcoma with a predominant epithelioid componentFigure 1 Physical findings in the patient. A) Multiple melanotic macules o
macule on the right cheek.(Figure 2A-F) and a definitive sarcomatous component
with prominent sex cord differentiation. An area of
endometriosis associated with the tumor was noted, rais-
ing the possibility that this pelvic tumor originated from
transformation of benign endometriosis tissue. The ma-
lignant cells were positive for estrogen receptor, pro-
gesterone receptor, inhibin and CD10, with the more
epithelioid areas positive for pancytokeratin, calretinin,
D2-40, and MOC-31. CK7, CK20, desmin, actin, S-100,
EMA, CEA, C-kit and CK-5/6 were negative. Differential
diagnosis included the diagnosis of Malignant Female
Adnexal Tumor of Wolffian Origin (FATWO). Evidence
against this diagnosis was the high-grade nature of this
tumor, the spindle cell component, and the negative
staining for CK7, positive staining for EMA and negative
staining for c-kit. Ovaries and fallopian tubes were nega-
tive for malignancy. The uterus had proliferative endo-
metrium and unremarkable myometrium. Microscopic
focal subserosal uterine tumor implants and para-
uterine soft tissue tumor implants were present. Pelvic
and cul de sac peritoneum were involved by tumor, and
foci of endometriosis were present. Lymph nodes were
negative for neoplasm (9 right para-aortic, 3 right exter-
nal iliac, 8 right obturator, 4 left para-aortic, 3 left exter-
nal iliac, and 6 left obturator nodes). In addition to the
two larger polyps, six other small bowel polyps (0.4 –
2.2 cm) were found and resected via small bowel en-
terotomies; pathology on all polyps was significant forn the fingertips characteristic or Peutz-Jeghers syndrome, B) Melanotic
Figure 2 Pathologic findings of the patient’s tumor. A) Area of endometriosis adjacent to the tumor. B) Endometrial stromal sarcoma, low grade.
C) Endometrial stromal sarcoma, low grade area, focally positive for CD10. D) Endometrial stromal sarcoma, epithelioid component. E) Endometrial
stromal sarcoma spindle cell component estrogen receptor positive F) Endometrial stromal sarcoma, epithelioid component, Pancytokeratin positive.
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Jeghers type polyp is a hamartomatous polyp with
smooth muscle arborization with occasional pseudo-
invasion. This patient had three polyps removed from
the large bowel a month before presenting to our insti-
tution; all three polyps were considered to be hyperplas-
tic by an outside pathologist. Upon review of these
polyps at our institution, it was determined that all three
polyps were hamartomatous with one consistent with
the Peutz-Jeghers type. Full gene sequencing and dele-
tion/duplication analysis of the STK11 gene was com-
pleted so that predictive testing could be offered to the
patient’s daughter; this genetic testing was not needed to
make the diagnosis of PJS in our patient. The diagnosisof Peutz-Jeghers syndrome was further confirmed with
the identification of a deleterious mutation in the STK11
gene, designated as 5’UTR_EX1del.
The patient received radiation therapy to the pelvis
followed by chemotherapy consisting of ifosfamide and
doxorubicin for 4 cycles. A repeat CT scan at the end of
chemotherapy showed subcapsular liver nodules suspi-
cious for metastasis. The patient was then started on letro-
zole, with development of progressive disease on this
treatment. She developed small bowel obstruction requir-
ing surgery with findings of high-grade small bowel ob-
struction requiring small bowel resection and multiple
metastatic nodules involving the right hemi-diaphragm
largest 3 cm in size and the transverse colon mesentery,
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ated neoplasm with a predominant epithelioid component
and a minimal spindle cell component. The epithelioid
component was pankeratin positive, with patchy EMA
positivity, patchy CK8/18 positivity and patchy membran-
ous CD99 positivity. Tumor cells were ER positive (60%)
and PR positive (5-10%) and were negative for inhibin,
melan A 103, desmin and SMA. The spindle cell compo-
nent had a myxoid morphology with patchy faint positivity
for SMMS-1. Subsequent treatment with everolimus and
anastrozole and later on with pazopanib and everolimus,
and gemcitabine and docetaxel, was not associated with a
clinical response. The patient had progressive disease lead-
ing to her death.
Additional genetic and immunohistochemical (IHC)
analysis of the tumor specimens were performed. Tumor
DNA was extracted from formalin fixed paraffin embed-
ded tissue. STK11 was sequenced using custom sequence
capture with targeted next generation sequencing. IHC of
the hamartomatous polyps and the sarcoma tumor from
paraffin embedded tissue was done utilizing human LKB1/
STK11 Affinity Purified Polyclonal Antibody (R & D
Systems).
STK11 tumor sequencing findings were consistent with
the patient's known germline deletion of exon 1. A "second
hit" somatic tumor mutation was not identified. IHC stud-
ies demonstrated STK-11 expression in the hamartoma-
tous polyp with decreased expression of STK-11 in the
sarcoma tumor tissue (Figure 3).
Conclusions
PJS patients have a higher risk for malignancies at a young
age, especially colorectal, breast, gynecologic, small bowel,
gastric, and pancreatic cancer. The relative cancer risk by
site is estimated to vary between 4.8 to 18 times that of
the general population, with a lifetime cumulative cancer
risk up to 93% [7]. The risk is much higher in female pa-
tients than male patients since gynecologic malignanciesFigure 3 Immunohistochemistry (IHC) for STK-11 of patient’s tissues.
stromal sarcoma. Images were obtained at 20X using Scanscope XT (Aperioand breast cancers are two of the most common malig-
nancies associated with PJS. Among the gynecologic ma-
lignancies, adenoma malignum of the uterine cervix,
adenocarcinoma of the endometrium and ovarian tumors
have been estimated to have a 15-fold higher incidence
than the general population [8].
Clinical suspicion for PJS needs to remain high in
order to make the diagnosis. The hyperpigmented mel-
anotic lesions may be missed since they may be few in
number, fade with age, and present most prominently on
the fingers and in the oral cavity without being notice-
able on the lips as in our patient (Figure 1A-B). The
hamartomatous polyps maybe misclassified as hyperplas-
tic polyps and therefore the connection between the
gynecological malignancy, the polyps and hyperpigmen-
tation may escape the diagnosis of PJS until adulthood
as occurred in our patient.
The most common ovarian neoplasm is the sex cords
tumor with annular tubules (SCTAT), which is typically
multifocal, calcified, and bilateral. Approximately 10% of
patients with PJS will develop SCTATs that require sur-
gery. These tumors are usually of a low malignant po-
tential and carry a good prognosis [6,9].
Adenoma malignum (ADM) is a rare variant type of
highly differentiated adenocarcinoma of the endocervical
glands that comprises 1-3% of all cervical adenocarcin-
omas; it can be aggressive and have a poor prognosis
despite its benign histologic appearance. The percentage
of patients with PJS who develop ADM is 5% or less,
and about 10% of patients with ADM have PJS [8,10].
Sarcomas are not usually associated with PJS. There
is only one case report of an epithelioid leiomyosar-
coma originating in a small bowel hamartomatous
polyp in a patient with PJS. The tumor showed an ag-
gressive behavior and by the time of resection, it had
metastasized to the liver. This is very unusual since
malignant transformation of the hamartomatous polyps
is rare [11]. There are no reports of gynecological orA) IHC for STK-11 of the hamartomatous polyp and B) the endometrial
Technologies, Vista, CA).
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patients with PJS.
We attempted to identify a "second hit" somatic tumor
mutation to conclusively link the tumor to the patient's
PJS diagnosis and germline STK11 mutation. The lack of
a "second hit" does not disprove that the patient's tumor
was related to her PJS diagnosis. "Second hit" somatic
mutations are only found in about 1 in 5 samples from
PJS intestinal polyps [12]. Explanations for the lack of
identification of a "second hit" include promoter hyper-
methylation, intronic mutations and complex rearrange-
ments. The relative decrease in the expression of the
STK11 protein in the sarcoma tumor compared to the
hamartomatous polyp as determined by IHC does sup-
port a link between the tumor and the patient’s PJS
diagnosis.
Identification of STK11 gene mutations in PJS have
allowed for the development of targeted molecular ther-
apy. STK11 mutations are associated with activation of
the mTOR pathway. mTOR inhibitors have been devel-
oped for clinical use in organ transplantation and treat-
ment of renal cancers. The mTOR inhibitors have been
reported in the treatment of a PJS patient with pancre-
atic cancer and could possibly serve as a second line
treatment for patients who have failed to respond to
other therapies [13]. The promise of these targeted ther-
apies for this rare cancer is another important reason for
oncologists to be more aware of PJS and its potential
diagnostic challenges. Unfortunately, the patient’s tumor
did not respond to mTOR inhibition.
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